文献速递瓣膜病与结构性心脏病心律失常

经导管心脏瓣膜感染性心内膜炎相关衰败的外科移出与结局:EXPLANT-TAVR国际注册研究

Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry.
PubMed 文献 · Eur Heart J · 2024-01-01

本研究基于EXPLANT-TAVR国际注册研究,纳入2011至2022年间44个中心的372例经导管心脏瓣膜(THV)外科移出患者,其中184例(49.5%)因感染性心内膜炎(IE)移出,188例(50.5%)因生物瓣衰败(BVD)移出。结果显示IE患者30天和1年卒中率更高、ICU及住院时间更长,3年死亡率数值上更高但未达统计学差异。

要点

  • THV移出患者中近半数因感染性心内膜炎,其30天和1年卒中率显著高于BVD患者。
  • IE患者ICU及住院时间更长,但调整后住院、30天和1年死亡率组间无显著差异。
  • IE患者3年死亡率数值更高(43.9% vs 29.6%),但未达统计学显著。

核心结论

  • 因IE行THV移出的患者30天和1年卒中率更高、ICU及住院时间更长,3年死亡率数值更高但未达统计学差异。

研究设计与样本

  • EXPLANT-TAVR国际注册研究,纳入2011至2022年间44个中心共372例THV外科移出患者,比较IE与其他BVD机制患者的结局。

主要发现

  • IE患者184例(49.5%),BVD患者188例(50.5%)。
  • 调整后全队列住院、30天和1年死亡率分别为12.1%、16.1%和33.8%,组间无显著差异。

临床怎么用

  • 因IE行THV移出患者围术期及1年卒中风险较高,应加强神经功能监测与预防。
  • IE患者住院及ICU资源占用更多,需优化围术期管理流程。

局限性

  • IE患者样本量相对较小且事件数较少,3年死亡率差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Surgical explantation of transcatheter heart valves (THVs) is rapidly increasing, but there are limited data on patients with THV-associated infective endocarditis (IE). This study aims to assess the outcomes of patients undergoing THV explant for IE. METHODS: All patients who underwent THV explant between 2011 and 2022 from 44 sites in the EXPLANT-TAVR registry were identified. Patients with IE as the reason for THV explant were compared to those with other mechanisms of bioprosthetic valve dysfunction (BVD). RESULTS: A total of 372 patients from the EXPLANT-TAVR registry were included. Among them, 184 (49.5%) patients underwent THV explant due to IE and 188 (50.5%) patients due to BVD. At the index transcatheter aortic valve replacement, patients undergoing THV explant for IE were older (74.3 ± 8.6 vs. 71 ± 10.6 years) and had a lower Society of Thoracic Surgeons risk score [2.6% (1.8-5.0) vs. 3.3% (2.1-5.6), P = .029] compared to patients with BVD. Compared to BVD, IE patients had longer intensive care unit and hospital stays (P < .05) and higher stroke rates at 30 days (8.6% vs. 2.9%, P = .032) and 1 year (16.2% vs. 5.2%, P = .010). Adjusted in-hospital, 30-day, and 1-year mortality was 12.1%, 16.1%, and 33.8%, respectively, for the entire cohort, with no significant differences between groups. Although mortality was numerically higher in IE patients 3 years postsurgery (29.6% for BVD vs. 43.9% for IE), Kaplan-Meier analysis showed no significant differences between groups (P = .16). CONCLUSIONS: In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Marin-Cuartas M, Tang GHL, Kiefer P, et al. Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J. 2024. PMID: 38820201. doi:10.1093/eurheartj/ehae292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。